Stocktoria
Alzamend Neuro, Inc. ALZN
Alzamend Neuro, Inc. financials (annual)
Bars are annual figures from 2020 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| R&D expense | $3.6M | $1.4M | $6.5M | $7.4M | $5.2M | $1.3M | $1.1M |
| Operating income | -$8.8M | -$4.5M | -$9.9M | -$14.9M | -$12.3M | -$5.0M | -$4.4M |
| Interest expense | $6,619 | $18,029 | $10,101 | $7,701 | $46,524 | $142,421 | — |
| Net income | -$8.8M | -$4.5M | -$9.9M | -$14.9M | -$12.4M | -$5.0M | -$4.4M |
| EPS (diluted) | $-2.63 | $-11.32 | $-132.33 | $-22.89 | $-0.14 | — | — |
| Operating cash flow | -$8.1M | -$6.6M | -$8.3M | -$8.9M | -$6.6M | -$2.7M | -$2.3M |
| Cash & equivalents | $710,689 | $3.9M | $376,048 | $5.1M | $14.1M | $1.9M | $90,285 |
| Total assets | $2.1M | $4.6M | $631,588 | $5.9M | $14.5M | $2.9M | $1.8M |
| Total liabilities | $1.3M | $634,761 | $3.2M | $2.9M | $1.2M | $899,643 | — |
| Shareholders' equity | $733,211 | $4.0M | -$2.6M | $3.0M | $13.4M | $2.0M | $821,709 |
Computed from company filings · US · as of 2025-04-30. Facts plus Stocktoria's own computed scores — not investment advice.